{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:20:32Z","timestamp":1775236832274,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-01513-5","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T01:00:15Z","timestamp":1741222815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Regulatory considerations for successful implementation of digital endpoints in clinical trials for drug development"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-2914","authenticated-orcid":false,"given":"G\u00fcl","family":"Erdemli","sequence":"first","affiliation":[]},{"given":"Tina","family":"Murphy","sequence":"additional","affiliation":[]},{"given":"Sarah","family":"Walinsky","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/cts.13533","volume":"16","author":"ES Izmailova","year":"2023","unstructured":"Izmailova, E. S., AbuAsal, B., Hassan, H. E., Saha, A. & Stephenson, D. Digital technologies: Innovations that transform the face of drug development. Clin. Transl. Sci. 16, 1323\u20131330 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"1513_CR2","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource (Food and Drug Administration (US), 2016). FDA-NIH Biomarker Working Group. 2016 Jan 28 [Updated 2021 Jan 25]. Co-published by National Institutes of Health (US), Bethesda (MD)."},{"key":"1513_CR3","unstructured":"FDA. Digital Health Technologies for Remote Data Acquisition in Clinical Investigation. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/digital-health-technologies-remote-data-acquisition-clinical-investigations (2023). Accessed 5 Jan 2025."},{"key":"1513_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12553-023-00738-2","volume":"13","author":"S Askin","year":"2023","unstructured":"Askin, S., Burkhalter, D., Calado, G. & El Dakrouni, S. Artificial Intelligence Applied to clinical trials: opportunities and challenges. Health. Technol. 13, 203\u2013213 (2023).","journal-title":"Health. Technol."},{"key":"1513_CR5","unstructured":"EMA. EMA Regulatory Science to 2025: strategic reflection. EMA\/110706\/2020. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf (2020). Accessed 5 Jan 2025."},{"key":"1513_CR6","unstructured":"EMA. European Medicines Agency Questions and answers: Qualification of digital technology-based methodologies to support approval of medicinal products (EMA\/219860\/2020). https:\/\/www.ema.europa.eu\/en\/documents\/other\/questions-and-answers-qualification-digital-technology-based-methodologies-support-approval-medicinal-products_en.pdf (2020). Accessed 5 Jan 2025."},{"key":"1513_CR7","unstructured":"Directorate-General for Health and Food Safety. Recommendation paper on decentralised elements in clinical trials. Recommendation paper DCT, V01, dd 13 December 2022. https:\/\/health.ec.europa.eu\/latest-updates\/recommendation-paper-decentralised-elements-clinical-trials-2022-12-14_en (2022). Accessed 5 Jan 2025."},{"key":"1513_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cts.12602","volume":"12","author":"ES Izmailova","year":"2019","unstructured":"Izmailova, E. S. et al. Evaluation of Wearable Digital Devices in a Phase I Clinical Trial. Clin. Transl. Sci. 12, 247\u2013256 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"1513_CR9","doi-asserted-by":"publisher","first-page":"1210974","DOI":"10.3389\/fneur.2023.1210974","volume":"14","author":"AK Brem","year":"2023","unstructured":"Brem, A. K. et al. Digital endpoints in clinical trials of Alzheimer\u2019s disease and other neurodegenerative diseases: challenges and opportunities. Front. Neurol. 14, 1210974 (2023).","journal-title":"Front. Neurol."},{"key":"1513_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000512513","volume":"4","author":"L Rochester","year":"2020","unstructured":"Rochester, L. et al. A roadmap to inform development, validation and approval of digital mobility outcomes: the mobilise-D approach. Digit. Biomark. 4, 13\u201327 (2020).","journal-title":"Digit. Biomark."},{"key":"1513_CR11","unstructured":"EMA. Guideline on computerised systems and electronic data in clinical trials. 9 March 2023 EMA\/INS\/GCP\/112288\/2023. Good Clinical Practice Inspectors Working Group (GCP IWG). https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf (2023). Accessed 5 Jan 2025."},{"key":"1513_CR12","unstructured":"FDA. Framework for the Use of Digital Health Technologies in Drug and Biological Product Development. https:\/\/www.fda.gov\/media\/166396\/download?attachment (2023). Accessed 5 Jan 2025."},{"key":"1513_CR13","unstructured":"FDA Drug Development Tool (DDT) Qualification Programs. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-development-tool-ddt-qualification-programs. Accessed 5 Jan 2025."},{"key":"1513_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1038\/s41591-023-02459-5","volume":"29","author":"L Servais","year":"2023","unstructured":"Servais, L. et al. First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD. Nature. Med. 29, 2391\u20132392 (2023).","journal-title":"Nature. Med."},{"key":"1513_CR15","unstructured":"US Food and Drug Administration. DDT COA #000103: ActiMyo\u00ae. https:\/\/www.fda.gov\/drugs\/clinical-outcome-assessment-coa-qualification-program\/ddt-coa-000103-actimyor (2020). Accessed 5 Jan 2025."},{"key":"1513_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3233\/JND-230188","volume":"11","author":"M Rabbia","year":"2024","unstructured":"Rabbia, M. et al. Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy. J. Neuromuscul. Dis. 11, 701\u2013714 (2024).","journal-title":"J. Neuromuscul. Dis."},{"key":"1513_CR17","unstructured":"FDA. Medical Device Development Tool (MDDT) Summary of Evidence and Basis of Qualification Apple Atrial Fibrillation History Feature. https:\/\/www.fda.gov\/media\/178230\/download?attachment (2024). Accessed 5 Jan 2025."},{"key":"1513_CR18","unstructured":"FDA. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit for-Purpose Clinical Outcome Assessments (fda.gov). https:\/\/www.fda.gov\/media\/159500\/download (2022). Accessed 5 Jan 2025."},{"key":"1513_CR19","unstructured":"FDA. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making. APRIL 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory (2023). Accessed 5 Jan 2025."},{"key":"1513_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41746-023-00886-9","volume":"6","author":"A Bertha","year":"2023","unstructured":"Bertha, A. et al. Incorporating digitally derived endpoints within clinical development programs by leveraging prior work. Npj. Digit. Med. 6, 139 (2023).","journal-title":"Npj. Digit. Med."},{"key":"1513_CR21","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1124\/pr.120.000028","volume":"72","author":"MD Kruizinga","year":"2020","unstructured":"Kruizinga, M. D. et al. Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation. Pharmacol. Rev. 72, 899\u2013909 (2020).","journal-title":"Pharmacol. Rev."},{"key":"1513_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000509725","volume":"4","author":"C Manta","year":"2020","unstructured":"Manta, C., Patrick-Lake, B. & Goldsack, J. C. Digital measures that matter to patients: a framework to guide the selection and development of digital measures of health. Digit. Biomark. 4, 69\u201377 (2020).","journal-title":"Digit. Biomark."},{"key":"1513_CR23","unstructured":"FDA. Qualification Process for Drug Development Tools, Guidance for Industry and FDA Staff. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/qualification-process-drug-development-tools-guidance-industry-and-fda-staff (2020). Accessed 5 Jan 2025."},{"key":"1513_CR24","unstructured":"EMA. Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies. 28 July 2023 EMADOC-1700519818-1127132. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne-muscular-dystrophy-studies_en.pdf (2023). Accessed 5 Jan 2025."},{"key":"1513_CR25","unstructured":"Complete guide to GDPR compliance. https:\/\/gdpr.eu\/. Accessed 5 Jan 2025."},{"key":"1513_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/cts.13529","volume":"16","author":"ES Izmailova","year":"2023","unstructured":"Izmailova, E. S., Demanuele, C. & McCarthy, M. Digital health technology derived measures: Biomarkers or clinical outcome assessments? Clin. Transl. Sci. 16, 1113\u20131120 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"1513_CR27","unstructured":"FDA. Biomarker Qualification: Evidentiary Framework, Draft Guidance for Industry and FDA Staff. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/biomarker-qualification-evidentiary-framework (2018). Accessed 5 Jan 2025."},{"key":"1513_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf, R. M. Biomarker definitions and their applications. Exp. Biol. Med. 243, 213\u2013221 (2018).","journal-title":"Exp. Biol. Med."},{"key":"1513_CR29","unstructured":"\u00a7 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. (21 CFR 314.510). https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-314\/subpart-H\/section-314.510 (2024). Accessed 5 Jan 2025."},{"key":"1513_CR30","unstructured":"ICH Harmonised Tripartite Guideline, Statistical Principles for Clinical Trials E9 September. https:\/\/database.ich.org\/sites\/default\/files\/E9_Guideline.pdf (1998). Accessed 5 Jan 2025."},{"key":"1513_CR31","unstructured":"U.S.C. Title 21 - FOOD AND DRUGS (govinfo.gov) \u00a7356. Expedited approval of drugs for serious or life-threatening diseases or conditions. https:\/\/www.govinfo.gov\/content\/pkg\/USCODE-2013-title21\/html\/USCODE-2013-title21-chap9-subchapV-partA-sec356.htm. Accessed 5 Jan 2025."},{"key":"1513_CR32","unstructured":"FDA. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/formal-meetings-between-fda-and-sponsors-or-applicants-pdufa-products (2023). Accessed 5 Jan 2025."},{"key":"1513_CR33","unstructured":"EMA. European Medicines Agency Guidance for Applicants seeking scientific advice and protocol assistance.EMA\/4260\/2001 Rev. 14, Scientific Evidence Generation Department. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/european-medicines-agency-guidance-applicants-seeking-scientific-advice-and-protocol-assistance_en.pdf (2022). Accessed 5 Jan 2025."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01513-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01513-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01513-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:56:42Z","timestamp":1741265802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01513-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01513-5","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.E., T.M. and S.W. are employees of Novartis and may hold shares in the company but have no non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}